Immunoassay Detects Severe Fever with Thrombocytopenia Syndrome Virus
|
By LabMedica International staff writers Posted on 25 Apr 2016 |

Image: A scanning electron micrograph (SEM) of severe fever with thrombocytopenia syndrome virus (Photo courtesy of the Japanese National Institute of Infectious Diseases).
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease with a high case fatality rate, and is caused by the SFTS virus (SFTSV) and the disease is endemic to China, South Korea, and Japan.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Japanese National Institute of Infectious Diseases
Bio-Rad Laboratories
Latest Microbiology News
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read morePathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more




 Assay.jpg)



